SIRT2 and breast cancer: SIRT2‐deficient breast cancer cells exhibit increased acetylation at PKM2 K305, preventing PKM2 tetramerisation and thereby reducing PKM2 enzymatic activity, ultimately altering glucose metabolism and inhibiting tumour growth.246